Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atrial Fibrillation Data For Boehringer Ingelheim’s Dabigatran Due In Early 2009

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm completes enrollment in RE-LY trial, one of seven in the Phase III RE-VOLUTION program for the investigational antithrombotic.

You may also be interested in...



Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837

With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)

Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837

With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)

Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox

The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel